In 2022, three gene therapies ZYNTEGLO & SKYSONA (bluebird bio) and HEMGENIX (uniQure) were approved by the FDA. Learn from Managing Partner Geert-Jan Mulder, MD, how Forbion became involved. CEO VectorY and Forbion Operating Partner Sander van Deventer explains the scientific insight required to develop gene therapies and the critical role Forbion played in the development of these therapies.